A study of patients with chronic obstructive pulmonary disease (COPD) who were treated with a new GlaxoSmithKline Plc medicine compared with the standard of care, has shown a benefit for the new medicine in everyday clinical practice. ---Subscribe to MedNous to access this article--- Clinical Research Company News
